Frame Bio

Executive Summary

Frame Bio is a pre-clinical biotechnology company developing next-generation regenerative therapies for bone and connective tissue disorders, such as osteoporosis and collagen disorders. The company leverages a novel extracellular vesicle (EV) drug delivery platform, focusing on the interconnected 'skin-bone axis' to enhance the body's natural repair processes. Founded in 2021 and based in San Francisco, Frame Bio has not disclosed funding or valuation. As an early-stage private company, its progress depends on advancing its EV platform through preclinical studies, securing financing, and forming strategic partnerships. The regenerative medicine space is competitive, but Frame Bio's unique approach targeting the skin-bone axis could differentiate it if preclinical data proves promising.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data in osteoporosis model60% success
• 2026Series A financing round40% success
• TBDStrategic partnership for EV platform development30% success